UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Anti‐cancer stem cell activity of a hedgehog inhibitor GANT61 in estrogen receptor‐positive breast cancer cells

Cancer science, 2017-05, Vol.108 (5), p.918-930

2017

Volltextzugriff (PDF)

Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells

Breast cancer (Tokyo, Japan), 2017-09, Vol.24 (5), p.683-693

2017

Volltextzugriff (PDF)

Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells

Breast cancer (Tokyo, Japan), 2021-01, Vol.28 (1), p.206-215

2021

Volltextzugriff (PDF)

Multiplex PCR analysis of apocrine lesions shows frequent PI3K–AKT pathway mutations in both benign and malignant apocrine breast tumors

Medical molecular morphology, 2020-03, Vol.53 (1), p.15-20

2020

Volltextzugriff (PDF)

Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions

BMC cancer, 2020-10, Vol.20 (1), p.944-944, Article 944

2020

Volltextzugriff (PDF)

Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics

Breast cancer (Tokyo, Japan), 2009-10, Vol.16 (4), p.275-280

Kurebayashi, Junichi

2009

Volltextzugriff (PDF)

CD1d- and PJA2-related immune microenvironment differs between invasive breast carcinomas with and without a micropapillary feature

BMC cancer, 2019-01, Vol.19 (1), p.76-76, Article 76

2019

Volltextzugriff (PDF)

Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011

Breast cancer (Tokyo, Japan), 2015-05, Vol.22 (3), p.235-244

2015

Volltextzugriff (PDF)

Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells

Breast cancer (Tokyo, Japan), 2020-05, Vol.27 (3), p.415-425

2020

Volltextzugriff (PDF)

Preparation of a novel antiserum to aromatase with high affinity and specificity: Its clinicopathological significance on breast cancer tissue

PloS one, 2017-05, Vol.12 (5), p.e0177439-e0177439

2017

Volltextzugriff (PDF)

Phosphorylated HER3 and FITC-labeled trastuzumab immunohistochemistry in patients with HER2-positive breast cancer treated with adjuvant trastuzumab

Medical molecular morphology, 2019-06, Vol.52 (2), p.106-113

2019

Volltextzugriff (PDF)

Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative study

Breast cancer (Tokyo, Japan), 2017-01, Vol.24 (1), p.161-170

2017

Volltextzugriff (PDF)

Correction: Preparation of a novel antiserum to aromatase with high affinity and specificity: Its clinicopathological significance on breast cancer tissue

PloS one, 2017-08, Vol.12 (8), p.e0183202-e0183202

2017

Volltextzugriff (PDF)

A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer

Breast cancer (Tokyo, Japan), 2021-05, Vol.28 (3), p.684-697

2021

Volltextzugriff (PDF)

Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells

Breast cancer (Tokyo, Japan), 2016-05, Vol.23 (3), p.425-436

2016

Volltextzugriff (PDF)

Eribulin Regresses a Cisplatinum-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model

Anticancer research, 2020-05, Vol.40 (5), p.2475-2479

2020

Volltextzugriff (PDF)

Comprehensive immunohistochemical analyses on expression levels of hedgehog signaling molecules in breast cancers

Breast cancer (Tokyo, Japan), 2018-11, Vol.25 (6), p.759-767

2018

Volltextzugriff (PDF)

Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype

BMC cancer, 2010-10, Vol.10 (1), p.568-568, Article 568

2010

Volltextzugriff (PDF)

A giant axillary mass treated as breast cancer metastasis

KAWASAKI MEDICAL JOURNAL, 2021, Vol.47, p.1-6

2021

Volltextzugriff (PDF)

Cost analysis of leuprorelin acetate in Japanese pre-menopausal breast-cancer patients: comparison between 6-month and 3-month depot formulations

Journal of medical economics, 2017-11, Vol.20 (11), p.1163-1169

2017

Volltextzugriff (PDF)

A Case of Takotsubo syndrome after Surgery for Papillary Thyroid Cancer

KAWASAKI MEDICAL JOURNAL, 2021, Vol.47, p.69-75

2021

Volltextzugriff (PDF)

Nuclear cysteine cathepsin variants in thyroid carcinoma cells

Biological chemistry, 2010-08, Vol.391 (8), p.923-935

2010

Volltextzugriff (PDF)

A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer

Breast cancer (Tokyo, Japan), 2016-05, Vol.23 (3), p.499-509

2016

Volltextzugriff (PDF)

Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells

Breast cancer (Tokyo, Japan), 2014-01, Vol.21 (1), p.75-85

2014

Volltextzugriff (PDF)

Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance

Breast cancer (Tokyo, Japan), 2003-04, Vol.10 (2), p.112-119

Kurebayashi, Junichi

2003

Volltextzugriff (PDF)

1 – 25 von 199

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(146)
Mit Volltextzugriff
(154)

Publikationsform

Artikel
(198)
Berichte
(1)

Sprache

Englisch
(158)
Japanisch
(48)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Anti‐cancer stem cell activity of a hedgehog inhibitor GANT61 in estrogen receptor‐positive breast cancer cells

Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells

Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells

Multiplex PCR analysis of apocrine lesions shows frequent PI3K–AKT pathway mutations in both benign and malignant apocrine breast tumors

Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions

Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics

CD1d- and PJA2-related immune microenvironment differs between invasive breast carcinomas with and without a micropapillary feature

Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011

Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells

Preparation of a novel antiserum to aromatase with high affinity and specificity: Its clinicopathological significance on breast cancer tissue

Phosphorylated HER3 and FITC-labeled trastuzumab immunohistochemistry in patients with HER2-positive breast cancer treated with adjuvant trastuzumab

Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative study

Correction: Preparation of a novel antiserum to aromatase with high affinity and specificity: Its clinicopathological significance on breast cancer tissue

A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer

Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells

Eribulin Regresses a Cisplatinum-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model

Comprehensive immunohistochemical analyses on expression levels of hedgehog signaling molecules in breast cancers

Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype

A giant axillary mass treated as breast cancer metastasis

Cost analysis of leuprorelin acetate in Japanese pre-menopausal breast-cancer patients: comparison between 6-month and 3-month depot formulations

A Case of Takotsubo syndrome after Surgery for Papillary Thyroid Cancer

Nuclear cysteine cathepsin variants in thyroid carcinoma cells

A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer

Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells

Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance

Suchergebnisse filtern